AUG 22, 2013 5:00 PM PDT

Clinical Utility Potential of Epigenetic Aberrations in Human Solid Tumors

Speaker
  • Chief of Scientific Intelligence, Director of Molecular Oncology, John Wayne Cancer Institute

Abstract
As Chief of Scientific Intelligence at the John Wayne Cancer Institute, Dr. Hoon interacts with external academic, industry, and government agencies to develop innovative translational research opportunities. He has coauthored more than 250 peer-reviewed articles and reviews, primarily related to translational molecular oncology of human solid tumors. He has over 25 patents on his studies. As founding Director of the Department of Molecular Oncology, Dr. Hoon continues to pioneer investigations of RNA/genomic/epigenomic biomarkers for diagnostic, prognostic and predictive assessment of residual tumor cells. He also spearheads investigations of circulating DNA/miRNA biomarkers for staging cancer in patients enrolled in phase II/III clinical trials. The Department's focus on biomarker expression in both tissue and body-fluid specimens gives it a uniquely broad scope. Dr. Hoon's team has developed diagnostic tissue biomarkers for molecular staging of sentinel lymph nodes and classification of human solid tumors such as melanoma, breast cancer and gastrointestinal cancer. Dr. Hoon also has pioneered development of blood-based nucleic-acid and tumor-cell biomarkers as prognostic tools. In the last decade he and his team have designed and conducted biomarker companion studies as part of multicenter international clinical trials. On the therapeutic front, Dr. Hoon is examining functional genomic and epigenomic changes as potential targets for development of novel approaches to treat or prevent malignancy. Dr. Hoon and the Department are funded by the National Institutes of Health/National Cancer Institute, the California Breast Cancer Research Program, Susan G. Komen for the Cure, Adelson Melanoma Research Foundation, the United States Department of Defense, and the pharma-biotech industry. Dr. Hoon has served on several review study sections as a permanent member for the National Cancer Institute, and was a founding member of NCI's Cancer Biomarker Study Section. The Department of Molecular Oncology consists of over 20 MD/PhD scientists and research technicians focused on translation molecular oncology. Some of the major ongoing collaborations include: Leiden University Medical Center, Netherlands; Genome Institute Singapore, Biopolis; Broad Institute of MIT and Harvard; Keio University; MD Anderson, and Melanoma Institute Australia. Dr. Hoon has trained more than 60 postdoctoral oncology fellows, who now hold faculty appointments in numerous academic institutions.    

Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
MAR 30, 2022 6:00 AM PDT
MAR 30, 2022 6:00 AM PDT
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic...
MAY 24, 2022 11:00 AM PDT
MAY 24, 2022 11:00 AM PDT
Date: May 24, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 7:00pm (CEST) NGS tumor profiling has become the mainstay of modern cancer therapy. Several NCCN-guided and FDA-approved therapies are c...
AUG 17, 2022 10:00 AM PDT
AUG 17, 2022 10:00 AM PDT
DATE: October 22, 2020 TIME: 8:00am PDT, 11:00am EDT Detection and/or amplification of target DNA sequences by polymerase chain reaction (PCR) is a prevalent method in molecular biology. PCR...
AUG 09, 2022 8:00 AM PDT
AUG 09, 2022 8:00 AM PDT
Date: August 09, 2022 Time: 8:00am (PDT), 11:00pm (EDT), 5:00pm (CEST) Regulatory T cells (Tregs) are an important T cell subpopulation that maintains immunological homeostasis. Today, Treg-...
Loading Comments...
Show Resources